Articles

Pharmacy’s Emerging Influence and the Roles Pharmacists Play

Leaders in oncology pharmacy tackle some of the biggest issues in the field today in a pre-summit professional development session.

Cancer Centers and the Integrated Health Delivery Systems and the Cancer Care Value Perspectives

Conference Correspondent

Stakeholders address the challenge of integrating high-cost therapies into cancer care delivery.

Insurance Payers and the Cancer Care Value Perspectives

Conference Correspondent

Payers identify strategies for promoting value-based, high-quality cancer care.

Keynotes Highlight a Successful Summit—Stellar Duo Delivers Outstanding Talks

Conference Correspondent

A pair of distinguished keynote speakers gave attendees a rare behind-the-scenes look at healthcare policy decisions at the highest levels.

Working with Integrated Health Delivery Systems in Cancer Care Ecosystem

Conference Correspondent

The Summit kicked off with opening remarks and the first of the event’s in-depth pre-summit professional development sessions—designed to take a deep dive into select topics.

Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News

By Yvette Florio Lane

Breast Cancer, FDA Approvals, News & Updates, In the News, Multiple Myeloma, Pediatric Cancer

Web Exclusives

The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer.

FDA on In Vitro Diagnostics, Vaping; Cost of Novel Treatments

FDA Approvals, News & Updates, In the News, NCCN Guidelines

Web Exclusives

FDA issues finalized guidelines for use of in vitro diagnostics in oncology drug trials and warnings on vaping; new findings report patients bear more costs when MBC treatment is not concordant with NCCN guidelines.

First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer

By Chase Doyle

Breast Cancer

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO

Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer

By Wayne Kuznar

Lung Cancer, Solid Tumors, Personalized Medicine

August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO